A review of the pharmacology and clinical efficacy of brivaracetam

Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity than levetiracetam, the first AED acting on SV2A....

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Pavel, Diaz, Anyzeila, Gasalla, Teresa, Whitesides, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783144/
https://www.ncbi.nlm.nih.gov/pubmed/29403319
http://dx.doi.org/10.2147/CPAA.S114072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783144/
https://www.ncbi.nlm.nih.gov/pubmed/29403319
http://dx.doi.org/10.2147/CPAA.S114072

Ejemplares similares